Heron Therapeutics: Update After HTX-011 Nerve Block Results [Seeking Alpha]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Seeking Alpha
Summary Heron Therapeutics ( HRTX ) rallied last week after reporting positive phase 2b results of HTX-011 in two nerve block procedures. The company also announced that HTX-011 received Breakthrough Therapy Designation from the FDA. The phase 2b results confirm HTX-011’s excellent efficacy and safety profile, though the company does not seem interested in pursuing this indication immediately, at least based on what CEO Quart said on last week’s investor call. I am increasing my price target from $35 to $45 and after including the additional shares to be issued in this week's offering. Heron remains a core holding in our Growth Stock Forum model portfolio despite gains reaching almost 200% since the stock was added to the portfolio in early 2017. HTX-011 confirms good efficacy and safety profile in two phase 2b nerve block trials Heron reported positive phase 2b results of HTX-011 in two nerve block procedures. The outcome is not surprising since HTX-011 has already been
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024PR Newswire
- Heron Therapeutics, Inc. (NASDAQ: HRTX) is now covered by analysts at Capital One Financial Co.. They set an "overweight" rating and a $6.00 price target on the stock.MarketBeat
- Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain [Seeking Alpha]Seeking Alpha
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City [Yahoo! Finance]Yahoo! Finance
HRTX
Earnings
- 3/12/24 - Beat
HRTX
Sec Filings
- 4/19/24 - Form 4
- 4/19/24 - Form PRE
- 4/19/24 - Form 4
- HRTX's page on the SEC website